BlackRock, Inc. 13D and 13G filings for Cue Biopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-07 5:09 pm Sale |
2024-01-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,247,978 4.980% |
-90,787 (-3.88%) |
Filing |
| 2024-01-31 2:08 pm Purchase |
2023-12-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,338,765 5.200% |
1,506,840 (+181.13%) |
Filing |
| 2022-07-08 4:57 pm Sale |
2022-06-30 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
831,925 2.400% |
-1,458,344 (-63.68%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,290,269 7.200% |
127,291 (+5.88%) |
Filing |
| 2021-01-29 09:56 am Purchase |
2020-12-31 | 13G | Cue Biopharma, Inc. CUE |
BLACKROCK INC BLK |
2,162,978 7.100% |
775,309 (+55.87%) |
Filing |